This site is intended for health professionals only

Published on 24 June 2010

Share this story:

MAP reports positive migraine data


A pharmaceutical company is to report positive analysis showing that its migraine drug is effective even when taken in the late stages of an attack.

MAP Pharmaceuticals studied 771 patients and found the inhaled drug Levadex was effective when taken at the initial stages of a moderate to severe migraine and up to eight hours later.

Stewart Tepper, MD, director of research for the Centre for Headache and Pain at the Cleveland Clinic, said: “Several published studies have shown that the efficacy of triptans is reduced significantly when treatment is delayed.

“However, many patients may be unable or unwilling to treat migraine early in an attack.

“Patients are looking to remedy this with a therapy that works when administered at any time during the migraine cycle.”

The Freedom-301 study is said to have already met key effectiveness and safety standards and several secondary goals.

Levadex is administered in hospitals and doctors’ surgeries.

Copyright Press Association 2010


Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine